Jun J Yang

List of Publications by Year
in descending order

182 papers	12,800 citations	25034 57 h-index	27406 106 g-index
192 all docs	192 docs citations	192 times ranked	13885 citing authors

#	Article	IF	Citations
1	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. Haematologica, 2022, 107, 371-380.	3.5	5
2	Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia. Pharmacogenetics and Genomics, 2022, 32, 60-66.	1.5	7
3	ABCC4, ITPA, NUDT15, TPMT and their interaction as genetic predictors of 6-mercaptopurine intolerance in chinese patients with acute lymphoblastic leukemia. Pediatric Hematology and Oncology, 2022, 39, 254-266.	0.8	4
4	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia. JAMA Oncology, 2022, 8, 354.	7.1	35
5	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nature Genetics, 2022, 54, 170-179.	21.4	29
6	Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemia. Blood Advances, 2022, 6, 2496-2509.	5.2	7
7	Molecular Mechanisms of ARID5B-Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2022, 114, 1287-1295.	6.3	10
8	Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nature Communications, 2022, 13, 2801.	12.8	25
9	Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia, 2022, 36, 1749-1758.	7.2	36
10	PharmGKB summary: acyclovir/ganciclovir pathway. Pharmacogenetics and Genomics, 2022, 32, 201-208.	1.5	2
11	Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma. Cell Reports, 2022, 39, 111000.	6.4	8
12	Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood Advances, 2022, 6, 3386-3397.	5.2	8
13	Race, Genotype, and Azathioprine Discontinuation. Annals of Internal Medicine, 2022, 175, 1092-1099.	3.9	14
14	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children. Journal of the National Cancer Institute, 2021, 113, 933-937.	6.3	9
15	Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. Blood, 2021, 137, 364-373.	1.4	37
16	GATA3 rs3824662A allele in Bâ€cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis. American Journal of Hematology, 2021, 96, E71-E74.	4.1	5
17	Effects of NT5C2 Germline Variants on 6â€Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2021, 109, 1538-1545.	4.7	5
18	Association ofGATA3Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2021, 113, 408-417.	6.3	16

#	Article	IF	Citations
19	Cancer health disparities in racial/ethnic minorities in the United States. British Journal of Cancer, 2021, 124, 315-332.	6.4	447
20	Crystal structures of NUDT15 variants enabled by a potent inhibitor reveal the structural basis for thiopurine sensitivity. Journal of Biological Chemistry, 2021, 296, 100568.	3.4	8
21	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature Cancer, 2021, 2, 284-299.	13.2	70
22	An international retrospective study for tolerability of 6-mercaptopurine on NUDT15 bi-allelic variants in children with acute lymphoblastic leukemia. Haematologica, 2021, 106, 2026-2029.	3.5	7
23	Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation. Blood, 2021, 138, 331-343.	1.4	46
24	Understanding the Origins of Loss of Protein Function by Analyzing the Effects of Thousands of Variants on Activity and Abundance. Molecular Biology and Evolution, 2021, 38, 3235-3246.	8.9	65
25	Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. Leukemia, 2021, 35, 3078-3091.	7.2	15
26	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Diseaseâ€“Directed Therapy. Blood Cancer Discovery, 2021, 2, 326-337.	5.0	71
27	Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase. Cancer Chemotherapy and Pharmacology, 2021, 88, 655-664.	2.3	5
28	Pharmacogenomics for Drug Dosing in Children: Current Use, Knowledge, and Gaps. Journal of Clinical Pharmacology, 2021, 61, S188-S192.	2.0	5
29	Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discovery, 2021, 11, 2846-2867.	9.4	83
30	NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir. Nature Communications, 2021, 12, 4181.	12.8	11
31	Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. Clinical Pharmacology and Therapeutics, 2021, 110, 559-562.	4.7	6
32	Practical Considerations for Using RNA Sequencing in Management of B-Lymphoblastic Leukemia. Journal of Molecular Diagnostics, 2021, 23, 1359-1372.	2.8	6
33	Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncology, The, 2021, 22, 1322-1332.	10.7	42
34	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	8.2	20
35	17-DMAG dually inhibits Hsp90 and histone lysine demethylases in alveolar rhabdomyosarcoma. IScience, 2021, 24, 101996.	4.1	7
36	NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells. Journal of Cellular and Molecular Medicine, 2021, 25, 10521-10533.	3.6	5

#	Article	IF	Citations
37	NUDT15 variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia. Blood Advances, 2021, 5, 5420-5428.	5.2	4
38	KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma. Nature Communications, 2021, 12, 7204.	12.8	22
39	The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead. Clinical Pharmacology and Therapeutics, 2020, 107, 176-180.	4.7	21
40	Treatment of Testicular Relapse of B-cell Acute Lymphoblastic Leukemia With CD19-specific Chimeric Antigen Receptor T Cells. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 366-370.	0.4	19
41	ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2020, 26, 256-264.	7.0	25
42	Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance. Cancer Research, 2020, 80, 5189-5202.	0.9	9
43	FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia. Scientific Reports, 2020, 10, 12074.	3.3	6
44	Therapy-induced mutagenesis in relapsed ALL is supported by mutational signature analysis. Blood, 2020, 136, 2235-2237.	1.4	1
45	Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment. Blood, 2020, 136, 2955-2958.	1.4	3
46	Cell Fate Decisions: The Role of Transcription Factors in Early B-cell Development and Leukemia. Blood Cancer Discovery, 2020, 1, 224-233.	5.0	17
47	The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Contextâ€“Dependent Manner in Pediatric Acute Lymphoblastic Leukemia. Molecular Cancer Research, 2020, 18, 1153-1165.	3.4	20
48	Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction. Nature Metabolism, 2020, 2, 635-647.	11.9	150
49	Deficiency of PTEN and CDKN2A Tumor-Suppressor Genes in Conventional and Chondroid Chordomas: Molecular Characteristics and Clinical Relevance . OncoTargets and Therapy, 2020, Volume 13, 4649-4663.	2.0	13
50	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 329-344.	13.2	44
51	Discovery of regulatory noncoding variants in individual cancer genomes by using cis-X. Nature Genetics, 2020, 52, 811-818.	21.4	47
52	Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq. Leukemia, 2020, 34, 2418-2429.	7.2	19
53	Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5394-5401.	7.1	95
54	Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia. JAMA Oncology, 2020, 6, 358.	7.1	159

#	Article	IF	Citations
55	Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia. Blood Cancer Discovery, 2020, 1, 96-111.	5.0	93
56	Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood, 2020, 135, 41-55.	1.4	171
57	Pharmacogenomics and ALL treatment: How to optimize therapy. Seminars in Hematology, 2020, 57, 130-136.	3.4	9
58	Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia. Blood, 2020, 136, 1161-1168.	1.4	9
59	Genetic defects in hematopoietic transcription factors and predisposition to acute lymphoblastic leukemia. Blood, 2019, 134, 793-797.	1.4	37
60	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood, 2019, 134, 1227-1237.	1.4	37
61	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. Journal of Clinical Oncology, 2019, 37, 3377-3391.	1.6	169
62	International Collaboration to Save Children With Acute Lymphoblastic Leukemia. Journal of Global Oncology, 2019, 5, 1-2.	0.5	9
63	Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study. Clinical Breast Cancer, 2019, 19, 225-235.e2.	2.4	4
64	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. Journal of the National Cancer Institute, 2019, 111, 1350-1357.	6.3	32
65	Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. Genetics in Medicine, 2019, 21, 2145-2150.	2.4	72
66	Is There Etiologic Heterogeneity between Subtypes of Childhood Acute Lymphoblastic Leukemia? A Review of Variation in Risk by Subtype. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 846-856.	2.5	26
67	Mechanisms of NT5C2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics, 2019, 18, 1887-1895.	4.1	17
68	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nature Communications, 2019, 10, 5348.	12.8	58
69	Pharmacogene Variation Consortium Gene Introduction: <scp>NUDT15</scp>. Clinical Pharmacology and Therapeutics, 2019, 105, 1091-1094.	4.7	45
70	Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on <scp>TPMT</scp> and <scp>NUDT</scp>15 Genotypes: 2018 Update. Clinical Pharmacology and Therapeutics, 2019, 105, 1095-1105.	4.7	428
71	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics, 2019, 51, 296-307.	21.4	384
72	Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nature Reviews Clinical Oncology, 2019, 16, 227-240.	27.6	132

#	Article	IF	Citations
73	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood, 2019, 133, 724-729.	1.4	44
74	RNA Sequencing in Childhood B-Lymphoblastic Leukemia Improves Molecular and Risk Assignment. Blood, 2019, 134, 651-651.	1.4	1
75	Effect of Dasatinib Vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized, Open-Label, Multicenter Study of the Chinese Children's Cancer Group. Blood, 2019, 134, 828-828.	1.4	0
76	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. Blood, 2019, 134, 649-649.	1.4	5
77	MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death and Disease, 2018, 9, 220.	6.3	46
78	Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation. Leukemia, 2018, 32, 1393-1403.	7.2	27
79	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 33, 937-948.e8.	16.8	142
80	PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood, 2018, 131, 2256-2261.	1.4	49
81	Global efforts toward the cure of childhood acute lymphoblastic leukaemia. The Lancet Child and Adolescent Health, 2018, 2, 440-454.	5.6	83
82	Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood, 2018, 131, 2466-2474.	1.4	43
83	MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. Haematologica, 2018, 103, 830-839.	3.5	35
84	Combination of common and novel rare NUDT15 variants improves predictive sensitivity of thiopurine-induced leukopenia in children with acute lymphoblastic leukemia. Haematologica, 2018, 103, e293-e295.	3.5	24
85	The genetic risk of second cancers: should the therapy for acute lymphoblastic leukemia be individualized according to germline genetic makeup?. Expert Review of Precision Medicine and Drug Development, 2018, 3, 339-341.	0.7	2
86	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. Journal of Clinical Oncology, 2018, 36, 591-599.	1.6	121
87	Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11711-E11720.	7.1	192
88	Diplotype analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lymphoid neoplasms. Leukemia, 2018, 32, 2710-2714.	7.2	26
89	Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer. International Journal of Molecular Sciences, 2018, 19, 240.	4.1	29
90	An overview of disparities in childhood cancer: Report on the Inaugural Symposium on Childhood Cancer Health Disparities, Houston, Texas, 2016. Pediatric Hematology and Oncology, 2018, 35, 95-110.	0.8	25

#	Article	IF	Citations
91	Leukemia Risk Gene ARID5B is a Crucial Regulator of B-Cell Development. Blood, 2018, 132, 385-385.	1.4	2
92	Tolerable Dose of 6-Mercaptopurine and Prognostic Impact of NUDT15-Deficient Genotype in Childhood Acute Lymphoblastic Leukemia. Blood, 2018, 132, 4032-4032.	1.4	1
93	Abstract 222: Genome-wide association study of acute lymphoblastic leukemia in children with Down syndrome. , 2018, , .		0
94	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 565-565.	1.4	14
95	Mutational Landscape and Temporal Evolution during Treatment of Relapsed Acute Lymphoblastic Leukemia. Blood, 2018, 132, 917-917.	1.4	0
96	Whole-genome noncoding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations. Blood, 2017, 129, 3264-3268.	1.4	32
97	Epidemiology and Etiology of Childhood ALL. , 2017, , 1-27.		4
98	The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenetics and Genomics, 2017, 27, 236-239.	1.5	63
99	Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Research, 2017, 27, 185-195.	5.5	105
100	Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity. Cancer Chemotherapy and Pharmacology, 2017, 80, 287-293.	2.3	10
101	Rare gene variants in a patient with azathioprine-induced lethal myelosuppression. Annals of Hematology, 2017, 96, 2131-2133.	1.8	6
102	Philadelphia Chromosomeâ€“like Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 464-470.	0.4	84
103	Pharmacogenomics in acute lymphoblastic leukemia. Best Practice and Research in Clinical Haematology, 2017, 30, 229-236.	1.7	27
104	Novel Gene and Network Associations Found for Acute Lymphoblastic Leukemia Using Caseâ€“Control and Family-Based Studies in Multiethnic Populations. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1531-1539.	2.5	7
105	Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Research, 2017, 77, 4626-4638.	0.9	42
106	Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood, 2017, 130, 1209-1212.	1.4	90
107	Family-based exome-wide association study of childhood acute lymphoblastic leukemia among Hispanics confirms role of ARID5B in susceptibility. PLoS ONE, 2017, 12, e0180488.	2.5	13
108	A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Nature Communications, 2016, 7, 10635.	12.8	44

#	Article	IF	Citations
109	Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia. EBioMedicine, 2016, 8, 173-183.	6.1	241
110	Familyâ€based exomeâ€wide assessment of maternal genetic effects on susceptibility to childhood Bâ€cell acute lymphoblastic leukemia in hispanics. Cancer, 2016, 122, 3697-3704.	4.1	15
111	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature Genetics, 2016, 48, 1481-1489.	21.4	231
112	NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nature Genetics, 2016, 48, 367-373.	21.4	389
113	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. Blood, 2016, 128, 1085-1085.	1.4	1
114	Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia. Blood, 2016, 128, 179-179.	1.4	0
115	Whole Transcriptome Sequencing Identified a Distinct Subtype of Acute Lymphoblastic Leukemia with Abnormalities of CREBBP and EP300. Blood, 2016, 128, 3912-3912.	1.4	0
116	Germline exome variation in children with acute lymphoblastic leukemia (ALL): Preliminary Findings. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S177.	0.4	0
117	Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood, 2015, 126, 2896-2899.	1.4	76
118	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	1.4	110
119	Genetic and clinical factors associated with obesity among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort. Cancer, 2015, 121, 2262-2270.	4.1	62
120	SVSI: Fast and Powerful Setâ€Valued System Identification Approach to Identifying Rare Variants in Sequencing Studies for Ordered Categorical Traits. Annals of Human Genetics, 2015, 79, 294-309.	0.8	9
121	Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood, 2015, 125, 3988-3995.	1.4	119
122	Estrogen receptor-Î± directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15172-15177.	7.1	110
123	Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature Genetics, 2015, 47, 263-266.	21.4	109
124	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Nature Communications, 2015, 6, 7553.	12.8	72
125	The Role of Histone Demethylase KDM4B in Myc Signaling in Neuroblastoma. Journal of the National Cancer Institute, 2015, 107, djv080.	6.3	63
126	Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2015, 33, 1235-1242.	1.6	369

#	Article	IF	Citations
127	Negative feedbackâ€“defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nature Medicine, 2015, 21, 563-571.	30.7	141
128	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncology, The, 2015, 16, 1659-1666.	10.7	161
129	Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. Journal of Clinical Oncology, 2015, 33, 2938-2948.	1.6	747
130	Evaluation of a two-step iterative resampling procedure for internal validation of genome-wide association studies. Journal of Human Genetics, 2015, 60, 729-738.	2.3	17
131	Biology of Childhood Acute Lymphoblastic Leukemia. Pediatric Clinics of North America, 2015, 62, 47-60.	1.8	155
132	De Novo Purine Biosynthesis in Drug Resistance and Tumor Relapse of Childhood ALL. Blood, 2015, 126, 2627-2627.	1.4	2
133	NT5C2 As a Major Contributor to Thiopurine Resistance at ALL Relapse Via Multiple Mechanisms. Blood, 2015, 126, 446-446.	1.4	1
134	Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia. Cancer, 2014, 120, 955-962.	4.1	128
135	Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2014, 32, 949-959.	1.6	275
136	Seven In Absentia Homolog 2 (SIAH2) downregulation is associated with tamoxifen resistance in MCF-7 breast cancer cells. Journal of Surgical Research, 2014, 190, 203-209.	1.6	12
137	Evaluation of two-step iterative resampling procedure for internal validation of genome-wide association studies. BMC Bioinformatics, 2014, 15, P34.	2.6	0
138	A New System Identification Approach to Identify Genetic Variants in Sequencing Studies for a Binary Phenotype. Human Heredity, 2014, 78, 104-116.	0.8	19
139	ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression. Blood, 2014, 124, 791-791.	1.4	28
140	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 3722-3722.	1.4	0
141	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231.	21.4	270
142	Carboxymethyl chitosan-poly(amidoamine) dendrimer coreâ€“shell nanoparticles for intracellular lysozyme delivery. Carbohydrate Polymers, 2013, 98, 1326-1334.	10.2	23
143	Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 290-294.	21.4	264
144	Thiopurine S-Methyltransferase Pharmacogenetics in Childhood Acute Lymphoblastic Leukemia. Methods in Molecular Biology, 2013, 999, 273-284.	0.9	7

#	Article	IF	Citations
145	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nature Genetics, 2013, 45, 1494-1498.	21.4	264
146	Response. Journal of the National Cancer Institute, 2013, 105, 1512-1513.	6.3	6
147	Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. Journal of the National Cancer Institute, 2013, 105, 733-742.	6.3	208
148	CEBPE promoter SNPs, caught red handed? A commentary on identification of functional nucleotide and haplotype variants in the promoter of the CEBPE gene. Journal of Human Genetics, 2013, 58, 571-572.	2.3	0
149	ARID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2012, 30, 751-757.	1.6	165
150	Folate-Linked Drugs for the Treatment of Cancer and Inflammatory Diseases. Sub-Cellular Biochemistry, 2012, 56, 163-179.	2.4	23
151	Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood, 2012, 120, 4197-4204.	1.4	103
152	Characterization of in Vivo Disulfide-Reduction Mediated Drug Release in Mouse Kidneys. Molecular Pharmaceutics, 2012, 9, 310-317.	4.6	13
153	Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 878-878.	1.4	0
154	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations. Blood, 2012, 120, 877-877.	1.4	2
155	Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. International Journal of Data Mining and Bioinformatics, 2011, 5, 143.	0.1	11
156	PharmGKB summary. Pharmacogenetics and Genomics, 2011, 21, 679-686.	1.5	120
157	Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood, 2011, 118, 5218-5226.	1.4	180
158	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nature Genetics, 2011, 43, 237-241.	21.4	239
159	Genomic Technology Applied to Pharmacological Traits. JAMA - Journal of the American Medical Association, 2011, 306, 652-3.	7.4	3
160	Pharmacogenetic and Pharmacogenomic Considerations in the Biology and Treatment of Childhood Leukemia. Pediatric Oncology, 2011, , 163-189.	0.5	1
161	Focal 22q11.22 Loss Combined with IKZF1 Alterations Predict Very Poor Outcome in Childhood Acute Lymphoblastic Leukemia. Blood, 2011, 118, 741-741.	1.4	0
162	Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood, 2010, 116, 4874-4884.	1.4	370

#	Article	IF	Citations
163	Pharmacogenomics of pediatric acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy, 2010, 11, 1621-1632.	1.8	15
164	The Histone Demethylase JMJD2B Is Regulated by Estrogen Receptor Î± and Hypoxia, and Is a Key Mediator of Estrogen Induced Growth. Cancer Research, 2010, 70, 6456-6466.	0.9	167
165	VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2010, 116, 273-273.	1.4	4
166	High Throughput Transcriptome Sequencing of Pediatric Relapsed Acute Lymphoblastic Leukemia (ALL) Identifies Relapse Specific Mutations and Expression. Blood, 2010, 116, 3233-3233.	1.4	0
167	Integrated Analysis of Pharmacokinetic, Clinical, and SNP Microarray Data Using Projection onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. , 2009, , .		1
168	Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1Î± and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia. Molecular and Cellular Biology, 2009, 29, 2243-2253.	2.3	89
169	Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2009, 301, 393.	7.4	193
170	Role of Hypoxiaâ€Inducible Factors in Epigenetic Regulation via Histone Demethylases. Annals of the New York Academy of Sciences, 2009, 1177, 185-197.	3.8	98
171	Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted ^{99m}Tc-Radioimaging Agents. Molecular Pharmaceutics, 2009, 6, 790-800.	4.6	147
172	Etoposide pathway. Pharmacogenetics and Genomics, 2009, 19, 552-553.	1.5	41
173	Etoposide Sensitivity Does Not Predict MLL Rearrangements or Risk of Therapy-Related Acute Myeloid Leukemia. Clinical Pharmacology and Therapeutics, 2008, 84, 691-697.	4.7	9
174	Cholesterol Level Regulates Endosome Motility via Rab Proteins. Biophysical Journal, 2008, 94, 1508-1520.	0.5	64
175	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood, 2008, 112, 4178-4183.	1.4	179
176	Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia. Blood, 2008, 112, 14-14.	1.4	1
177	Characterization of the pH of Folate Receptor-Containing Endosomes and the Rate of Hydrolysis of Internalized Acid-Labile Folate-Drug Conjugates. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 462-468.	2.5	113
178	A novel spermatogenesis-specific uPAR gene expressed in human and mouse testis. Biochemical and Biophysical Research Communications, 2006, 342, 1223-1227.	2.1	13
179	Issues related to targeted delivery of proteins and peptides. AAPS Journal, 2006, 8, E466-E478.	4.4	90
180	Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 13872-13877.	7.1	300

#	Article	IF	Citations
181	Dentinogenesis imperfecta 1 with or without progressive hearing loss is associated with distinct mutations in DSPP. Nature Genetics, 2001, 27, 201-204.	21.4	302
182	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. SSRN Electronic Journal, 0, , .	0.4	0